Seretide for obstructive lung disease

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 3, 2002, Pages 341-350

  Chapman, Kenneth R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

2; Adherence; Agonist; Asthma; Chronic obstructive pulmonary disease; Combination therapy; Fluticasone; Inhaled corticosteroid; Salmeterol

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; OXEZE; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADRENAL SUPPRESSION; ADULT; AEROSOL; ARTICLE; ASTHMA; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; PATIENT COMPLIANCE; POWDER INHALER; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; DRUG COMBINATIONS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0036192777     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.3.341     Document Type: Article

References (72)

1. The costs of asthma
2. Trends in the cost of illness for asthma in the United States, 1985-1994
3. Direct and indirect costs of asthma in Canada, 1990
4. Asthma: 2. Trends in pharmacologic therapy
5. Drug therapy: Inhaled glucocorticoids for asthma
6. The assessment and treatment of asthma: A conference report
7. Regular inhaled β-agonist treatment in bronchial asthma
8. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol
9. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids
10. Pressurised metered dose inhalers: Chlorofluorocarbon to hydrofluoroalkane transition - Valve performance
11. Efficacy of salmeterol xinafoate in the treatment of COPD
12. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease
13. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate-to-severe chronic obstructive pulmonary disease: The ISOLDE trial
14. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
15. The Diskus device - A novel multi-dose powder inhaler
16. Relative safety and efficacy of inhaled corticosteroids
17. The Research Council of the Norwegian Thoracic Society. High-dose inhaled steroids in asthmatics: Moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis
18. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients
19. Therapeutic ratio of inhaled corticosteroids in adult asthma - A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function
20. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
21. A comparison of fluticasone proprionate, 1 mg daily, with beclomethasone diproprionate, 2 mg daily, in the treatment of severe asthma
22. Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma
23. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma
24. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: A double-blind, placebo-controlled study
25. Dose-response of inhaled drugs in asthma - An update
26. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis
27. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
28. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness
29. Rapid onset of tolerance to the bronchoprotective effect of salmeterol
30. 2-adrenoceptor agonist, salmeterol, on airway hyper-responsiveness in patients with mild asthma
31. Effect of long-term salmeterol treatment on exercise-induced asthma
32. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: A Canadian multicenter study
33. Salmeterol vs. theophylline - Sleep and efficacy outcomes in patients with nocturnal asthma
34. The efficacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies
35. 4 excretion
36. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol
37. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
38. Effect of inhaled formoterol and budesonide on exacerbation of asthma
39. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
40. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
41. Control of asthma in Canada: Failure to achieve guideline targets
42. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients
43. Adverse effects of inhaled corticosteroids
44. Effect of salmeterol on patients adherence to their prescribed refills for inhaled corticosteroids
45. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomised, double-blind, placebo-controlled trial
46. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
47. Salmeterol and fluticasone propionate (50/250 μg) administered as combination Diskus inhaler: As effective as when given via separate Diskus inhalers
48. Salmeterol/fluticasone (50/100 μg) combination inhaler: A new, effective and well-tolerated treatment for asthma
49. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
50. Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide)
51. 2-agonist therapy in asthma
52. 2-adrenergic receptor function in human nasal mucosa
53. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
54. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in children with asthma
55. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice-daily is more effective than budesonide 800 μg twice-daily in treating moderate to severe asthma
56. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
57. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice-daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma
58. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 μg vs. fluticasone propionate 100 μg in adults and adolescents with asthma. III: Results
59. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 μg vs. fluticasone propionate 250 μg in adults and adolescents with asthma. IV: Results
60. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500μg vs. fluticasone propionate 500 μg in patients with corticosteroid-dependent asthma. V: Results
61. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma
62. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice-daily and budesonide 800 μg twice-daily in the treatment of adults and adolescents with asthma
63. Guidelines for the assessment and management of chronic obstructive pulmonary disease
64. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: A single-centre, randomised, double-blind, placebo-controlled, crossover study
65. Salmeterol reduces dyspnoea and improves lung function in patients with COPD
66. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
67. Quality of life changes in COPD patients treated with salmeterol
68. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary
69. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease
70. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
71. EUROSCOP, ISOLDE and the Copenhagen City Lung Study
72. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers